🏛️ Verified NIH Record • Updated 2026-07-29
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (NCT05067283)
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Merck Sharp & Dohme LLC
🩺 Plain-English Summary (8th-Grade Level)
This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.
Who can join: Review the eligibility criteria below.
Location: Moffitt Cancer Center ( Site 0261) — Tampa, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (75 Sites)
Showing the first 25 of 75 sites.
- Moffitt Cancer Center ( Site 0261) — Tampa, Florida
- START Midwest ( Site 0267) — Grand Rapids, Michigan
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260) — Hackensack, New Jersey
- Laura and Isaac Perlmutter Cancer Center ( Site 0270) — New York, New York
- NEXT Virginia ( Site 0271) — Fairfax, Virginia
- MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0262) — Milwaukee, Wisconsin
- Instituto Alexander Fleming ( Site 0434) — Ciudad Autónoma de Buenos Aires, Buenos Aires
- Sanatorio Parque ( Site 0456) — Rosario, Santa Fe Province
- Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0438) — La Rioja,
- Chris O'Brien Lifehouse ( Site 0002) — Camperdown, New South Wales
- Liverpool Hospital-Medical Oncology ( Site 0001) — Liverpool, New South Wales
- Westmead Hospital ( Site 0006) — Westmead, New South Wales
- Monash Health-Oncology Research ( Site 0003) — Clayton, Victoria
- Cross Cancer Institute ( Site 0033) — Edmonton, Alberta
- The Moncton Hospital ( Site 0037) — Moncton, New Brunswick
- Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0030) — Hamilton, Ontario
- Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0036) — Kingston, Ontario
- Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0032) — Toronto, Ontario
- James Lind Centro de Investigacion del Cancer ( Site 0043) — Temuco, Araucania
- Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0041) — Santiago, Region M. de Santiago
- FALP-UIDO ( Site 0040) — Santiago, Region M. de Santiago
- Bradfordhill ( Site 0042) — Santiago, Region M. de Santiago
- Beijing Friendship Hospital Affiliate of Capital University-Oncology ( Site 0417) — Beijing, Beijing Municipality
- Fujian Cancer Hospital ( Site 0419) — Fuzhou, Fujian
- Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 0413) — Guangzhou, Guangdong
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
- QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Denver, Colorado
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California
Explore by condition: All Advanced Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.